Analysts Set Structure Therapeutics Inc. (NASDAQ:GPCR) Target Price at $85.71

Structure Therapeutics Inc. (NASDAQ:GPCR) has received an average recommendation of “Buy” from the six analysts that are presently covering the firm, MarketBeat.com reports. Six analysts have rated the stock with a buy rating. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $85.71.

GPCR has been the subject of several recent research reports. Lifesci Capital reiterated an “outperform” rating on shares of Structure Therapeutics in a research note on Tuesday, February 27th. Cantor Fitzgerald initiated coverage on shares of Structure Therapeutics in a research note on Tuesday. They issued an “overweight” rating and a $65.00 price target for the company.

Structure Therapeutics Stock Down 0.1 %

Structure Therapeutics stock opened at $40.25 on Tuesday. Structure Therapeutics has a 52-week low of $21.79 and a 52-week high of $75.02. The firm has a market cap of $1.88 billion and a PE ratio of -48.49. The company’s 50 day moving average is $41.60 and its two-hundred day moving average is $48.63.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Friday, March 8th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.04. On average, equities research analysts anticipate that Structure Therapeutics will post -0.96 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Structure Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Adage Capital Partners GP L.L.C. boosted its stake in Structure Therapeutics by 835.5% in the third quarter. Adage Capital Partners GP L.L.C. now owns 1,799,923 shares of the company’s stock valued at $90,752,000 after acquiring an additional 1,607,525 shares in the last quarter. Wellington Management Group LLP grew its stake in Structure Therapeutics by 312.6% during the 3rd quarter. Wellington Management Group LLP now owns 867,579 shares of the company’s stock worth $43,743,000 after buying an additional 657,310 shares during the last quarter. FMR LLC increased its position in Structure Therapeutics by 28.5% during the third quarter. FMR LLC now owns 1,590,335 shares of the company’s stock worth $80,185,000 after buying an additional 352,600 shares during the period. TD Asset Management Inc boosted its holdings in shares of Structure Therapeutics by 109.3% in the third quarter. TD Asset Management Inc now owns 152,176 shares of the company’s stock valued at $7,673,000 after acquiring an additional 79,467 shares during the period. Finally, Victory Capital Management Inc. acquired a new stake in shares of Structure Therapeutics in the third quarter valued at approximately $7,611,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.